Diagnostics channel feed

Weak Chi­na de­mand weighs on Il­lu­mi­na's sales

9 months ago
China

23andMe board re­jects Anne Wo­j­ci­c­ki’s take-pri­vate plan, re­quests changes

9 months ago
Deals

Il­lu­mi­na com­peti­tor El­e­ment Bio­sciences rais­es $277M in Se­ries D

10 months ago
Financing

Ther­mo Fish­er clos­es $3.1B Olink ac­qui­si­tion af­ter UK an­titrust re­view is cleared

10 months ago
Deals

Grail pi­o­neered mul­ti-can­cer tests. But the com­pa­ny’s rough pub­lic de­but shows the in­dus­try could be in trou­ble

10 months ago
Pharma

Il­lu­mi­na board agrees to spin off Grail rather than sell the can­cer di­ag­nos­tics firm

11 months ago
Deals

UK won’t or­der Grail’s can­cer test for 1M peo­ple this year, a set­back for di­vesti­ture plans

11 months ago

Il­lu­mi­na takes a step to­ward spin­ning off Grail, though keeps op­tion open for sale

Last year
Deals

DNA se­quenc­ing firm PacBio to lay off work­ers and shut­ter San Diego of­fice

Last year

FDA fi­nal­izes long-await­ed rule to bring lab tests un­der its purview

Last year
Pharma
FDA+

Lu­mi­cell nabs FDA ap­proval for drug-de­vice breast can­cer de­tec­tion sys­tem

Last year
Pharma
FDA+

Il­lu­mi­na re­ceives EU clear­ance for planned Grail di­vest­ment

Last year
Deals

Ic­ahn gives up seat on Il­lu­mi­na board, back­ing away from chal­lenge to di­ag­nos­tics com­pa­ny

Last year
Deals

Once a sci­en­tif­ic back­wa­ter, pro­tein re­search at­tracts bil­lion-dol­lar deals and high-pro­file pub­li­ca­tions

Last year
Discovery
In Focus

Freenome rais­es $254M for ear­ly can­cer de­tec­tion tests

Last year
Financing

In clash over sci­ence and na­tion­al se­cu­ri­ty, Chi­nese ri­val to Il­lu­mi­na strug­gles with US ex­pan­sion

Last year
China
In Focus

Dana­her out­does low fourth-quar­ter rev­enue ex­pec­ta­tions, fore­casts slow 2024

Last year
Financing

Lu­naD­NA, a con­nec­tor of pa­tients and phar­ma­ceu­ti­cals, to shut­ter

Last year

Rav­gen con­tin­ues its le­gal re­venge saga with a $57M ver­dict over Nat­era

Last year
Law

Ic­ahn or­dered to re­move law­suit’s con­fi­den­tial in­for­ma­tion that was sup­plied by Il­lu­mi­na board mem­ber

Last year

Ve­r­a­cyte to buy C2i Ge­nomics for up to $95M, in­cludes $70M up­front

Last year
Deals

Ex­clu­sive: Il­lu­mi­na board mem­bers al­lege ac­tivist di­rec­tor gave con­fi­den­tial in­for­ma­tion to Ic­ahn for use in law­suit

Last year
Law

Up­dat­ed: Delfi Di­ag­nos­tics hires Il­lu­mi­na’s chief com­mer­cial of­fi­cer as next CEO

Last year
People

Grail has big plans for its blood can­cer tests. The first step: Find­ing a new own­er

Last year
In Focus
First page Previous page 1234 Next page Last page
A service from the Financial Times